Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50 Day Moving Average - Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $9.11 and traded as low as $6.96. Seres Therapeutics shares last traded at $7.13, with a volume of 62,725 shares.

Analyst Ratings Changes

Several research firms have commented on MCRB. Chardan Capital reissued a "neutral" rating and issued a $6.00 target price (up from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. Wall Street Zen raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Finally, The Goldman Sachs Group decreased their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a report on Friday, March 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $73.67.

Seres Therapeutics Stock Performance

The stock has a market capitalization of $71.86 million, a P/E ratio of -35.78 and a beta of 2.62. The firm's fifty day simple moving average is $8.87 and its 200 day simple moving average is $13.70.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Analysts anticipate that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Avantax Advisory Services Inc. grew its holdings in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 37,866 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 48,013 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 89,995 shares during the last quarter. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.